The pharmaceutical industry has witnessed a resurgence of mergers and acquisitions (M&As) as companies seek to gain a competitive edge, accelerate innovation, and drive growth. By consolidating ...

Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...

Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...

This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks. The US has opened a formal trade investigation into how ...

Capital is flowing into CGTs, while outpatient CAR-T delivery reached 45% in 2025, expanding the number of administration sites requiring specialized, time-critical logistics support. Maintaining vein ...

Patient support services—supported directly or indirectly by pharma companies—have gone from a ‘nice to have’ feature to a ‘must have’ one in recent years. The reasons are not hard to find: the growth ...

Market growth is propelled by high-cost specialty therapies, payer friction, and complex access pathways, making hub and patient support infrastructure increasingly central to commercialization and ...

Intelliguard and Accucold have launched an RFID-enabled refrigerated cabinet to improve hospital medication tracking, visibility, and cold-chain control. AI-driven cold chain visibility is only as ...

DSCSA enforcement in 2025–2026 makes interoperable, package-level electronic traceability and saleable-returns verification a primary constraint; non-serialized, non-auditable architectures now create ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...